CNBX Pharmaceuticals Inc. (CNBX)
USD 0.01
(42.86%)
USD 0.01
(42.86%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.54 Million USD | 76.3% |
| 2022 | -3.52 Million USD | -10.57% |
| 2021 | -3.14 Million USD | 56.63% |
| 2020 | -7.24 Million USD | -134.29% |
| 2019 | 1.34 Million USD | 17.52% |
| 2018 | -3.72 Million USD | -103.18% |
| 2017 | -1.92 Million USD | -561.73% |
| 2016 | -278.42 Thousand USD | 47.85% |
| 2015 | -540.08 Thousand USD | -148.84% |
| 2014 | -218.08 Thousand USD | -271.25% |
| 2013 | -56.22 Thousand USD | -48.02% |
| 2012 | -21.54 Thousand USD | 43.93% |
| 2011 | -165.72 Thousand USD | -223.97% |
| 2010 | 56.31 Thousand USD | 149.0% |
| 2009 | -114.92 Thousand USD | -8262.0% |
| 2008 | 1408.00 USD | 106.36% |
| 2007 | -21.26 Thousand USD | -210.51% |
| 2006 | 20.02 Thousand USD | 1212.28% |
| 2005 | -1800.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -173.57 Thousand USD | -31.06% |
| 2024 Q1 | -132.43 Thousand USD | 75.25% |
| 2024 Q3 | -152.28 Thousand USD | 12.27% |
| 2023 Q1 | -303.6 Thousand USD | 74.68% |
| 2023 Q4 | -2.57 Million USD | -1833.39% |
| 2023 FY | - USD | 76.3% |
| 2023 Q2 | 2.18 Million USD | 819.91% |
| 2023 Q3 | -133.08 Thousand USD | -106.09% |
| 2022 Q3 | -586.17 Thousand USD | 13.76% |
| 2022 FY | - USD | -10.57% |
| 2022 Q1 | -1.05 Million USD | 5.09% |
| 2022 Q2 | -679.67 Thousand USD | 35.79% |
| 2022 Q4 | -1.19 Million USD | -104.56% |
| 2021 Q4 | -1.11 Million USD | -79.79% |
| 2021 FY | - USD | 56.63% |
| 2021 Q1 | -602.22 Thousand USD | 88.05% |
| 2021 Q2 | -611.36 Thousand USD | -1.52% |
| 2021 Q3 | -620.3 Thousand USD | -1.46% |
| 2020 FY | - USD | -134.29% |
| 2020 Q3 | -627.28 Thousand USD | 22.94% |
| 2020 Q2 | -813.98 Thousand USD | -6.5% |
| 2020 Q1 | -764.27 Thousand USD | -121.7% |
| 2020 Q4 | -5.03 Million USD | -703.24% |
| 2019 FY | - USD | 17.52% |
| 2019 Q3 | -733.94 Thousand USD | 13.26% |
| 2019 Q1 | -601.79 Thousand USD | 9.34% |
| 2019 Q2 | -846.11 Thousand USD | -40.6% |
| 2019 Q4 | 3.52 Million USD | 579.89% |
| 2018 Q1 | -531.81 Thousand USD | 54.03% |
| 2018 Q4 | -663.77 Thousand USD | 20.73% |
| 2018 FY | - USD | -103.18% |
| 2018 Q3 | -837.4 Thousand USD | 50.37% |
| 2018 Q2 | -1.68 Million USD | -217.27% |
| 2017 Q1 | -102.6 Thousand USD | -58.14% |
| 2017 Q4 | -1.15 Million USD | -145.63% |
| 2017 Q3 | -470.96 Thousand USD | -145.23% |
| 2017 FY | - USD | -561.73% |
| 2017 Q2 | -192.04 Thousand USD | -87.17% |
| 2016 FY | - USD | 47.85% |
| 2016 Q3 | -13.43 Thousand USD | 90.07% |
| 2016 Q1 | -49.69 Thousand USD | 75.36% |
| 2016 Q2 | -135.29 Thousand USD | -172.24% |
| 2016 Q4 | -64.88 Thousand USD | -383.08% |
| 2015 Q2 | -55.92 Thousand USD | 54.93% |
| 2015 FY | - USD | -148.84% |
| 2015 Q4 | -201.69 Thousand USD | -31.42% |
| 2015 Q3 | -153.47 Thousand USD | -174.43% |
| 2015 Q1 | -124.08 Thousand USD | 15.54% |
| 2014 Q4 | -146.9 Thousand USD | -492.42% |
| 2014 Q3 | -24.79 Thousand USD | 15.37% |
| 2014 Q2 | -29.3 Thousand USD | -107.07% |
| 2014 Q1 | -14.15 Thousand USD | 57.8% |
| 2014 FY | - USD | -271.25% |
| 2013 Q2 | -4650.00 USD | 69.21% |
| 2013 Q1 | -15.1 Thousand USD | 34.48% |
| 2013 Q3 | -4650.00 USD | 0.0% |
| 2013 FY | - USD | -48.02% |
| 2013 Q4 | -33.53 Thousand USD | -621.12% |
| 2012 Q2 | -1849.00 USD | 81.95% |
| 2012 Q1 | -10.24 Thousand USD | 88.6% |
| 2012 Q3 | -4000.00 USD | -116.33% |
| 2012 Q4 | -23.04 Thousand USD | -476.13% |
| 2012 FY | - USD | 43.93% |
| 2011 Q1 | -8808.00 USD | -155.81% |
| 2011 FY | - USD | -223.97% |
| 2011 Q4 | -89.9 Thousand USD | -151.4% |
| 2011 Q3 | -35.76 Thousand USD | -209.5% |
| 2011 Q2 | -11.55 Thousand USD | -31.18% |
| 2010 Q4 | 15.78 Thousand USD | -75.0% |
| 2010 Q3 | 63.12 Thousand USD | 3662.42% |
| 2010 Q2 | -1772.00 USD | 91.51% |
| 2010 Q1 | -20.87 Thousand USD | 80.53% |
| 2010 FY | - USD | 149.0% |
| 2009 FY | - USD | -8262.0% |
| 2009 Q4 | -107.21 Thousand USD | -12195.53% |
| 2009 Q3 | -872.00 USD | 33.99% |
| 2009 Q2 | -1321.00 USD | 76.03% |
| 2009 Q1 | -5510.00 USD | -176.61% |
| 2008 FY | - USD | 106.36% |
| 2008 Q2 | -1532.00 USD | 78.08% |
| 2008 Q1 | -6988.00 USD | -106.2% |
| 2008 Q3 | -1975.00 USD | -28.92% |
| 2008 Q4 | -1992.00 USD | -0.86% |
| 2007 Q2 | -9694.00 USD | -36.32% |
| 2007 Q3 | -1859.00 USD | 80.82% |
| 2007 Q4 | -3389.00 USD | -82.3% |
| 2007 FY | - USD | -210.51% |
| 2007 Q1 | -7111.00 USD | -120.96% |
| 2006 Q2 | -5514.00 USD | 8.36% |
| 2006 FY | - USD | 1212.28% |
| 2006 Q1 | -6017.00 USD | 0.0% |
| 2006 Q3 | -2381.00 USD | 56.82% |
| 2006 Q4 | 33.93 Thousand USD | 1525.16% |
| 2005 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 95.007% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 40.175% |
| SQZ Biotechnologies Company | -64.14 Million USD | 94.47% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 79.58% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 103.772% |
| Mesoblast Limited | -62.38 Million USD | 94.315% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -130.917% |
| Genus plc | 73.7 Million USD | 104.813% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 46.351% |
| Marizyme, Inc. | -34.28 Million USD | 89.653% |
| ContraFect Corporation | -64.99 Million USD | 94.543% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 59.565% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 21.634% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -153.03% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -34.13% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -52.637% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -584.688% |
| Accustem Sciences Inc. | -3.74 Million USD | 5.323% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 92.645% |
| EV Biologics, Inc. | -1.26 Million USD | -179.923% |
| Q BioMed Inc. | -617.62 Thousand USD | -474.294% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 199.3% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -460.874% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -55.264% |
| Biomind Labs Inc. | -1.03 Million USD | -242.855% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 135.912% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 50.47% |
| Skye Bioscience, Inc. | -13.54 Million USD | 73.818% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -138.468% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -14087.992% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 8.684% |
| IMV Inc. | -35.52 Million USD | 90.015% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 77.649% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -41.769% |
| GB Sciences, Inc. | -1.41 Million USD | -149.809% |
| Alpha Cognition Inc. | -9.7 Million USD | 63.454% |
| HST Global, Inc. | -5303.00 USD | -66786.63% |
| CSL Limited | 4.78 Billion USD | 100.074% |
| Halberd Corporation | -74.27 Thousand USD | -4675.237% |
| Enzolytics Inc. | -2.12 Million USD | -67.151% |
| Resverlogix Corp. | -11.74 Million USD | 69.792% |
| Affymax, Inc. | -14.29 Million USD | 75.187% |
| SYBLEU INC | -141.57 Thousand USD | -2405.455% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -15.801% |
| argenx SE | -216.02 Million USD | 98.358% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 93.59% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 391.454% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -136.639% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1036.269% |
| AVAX Technologies, Inc. | -6.11 Million USD | 41.973% |
| Zenith Capital Corp. | -8.6 Million USD | 58.785% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.574% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -20260.473% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -44.985% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1915.061% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 91.051% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -22.635% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -239.0% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 52851.309% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -102.686% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -84.652% |
| BioStem Technologies, Inc. | -7.55 Million USD | 53.043% |
| ONE Bio Corp. | 13.61 Million USD | 126.056% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1858.715% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -72.435% |
| Agentix Corp. | -1.37 Million USD | -158.574% |
| LadRx Corporation | 412.28 Thousand USD | 960.331% |
| Cell Source, Inc. | -4.27 Million USD | 16.981% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -865.903% |
| Regen BioPharma, Inc. | 1.46 Million USD | 341.958% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -278.569% |
| NovAccess Global Inc. | -1.03 Million USD | -242.772% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 140.062% |
| Itoco Inc. | -1.86 Million USD | -89.781% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -834.355% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -217.831% |
| Kadimastem Ltd | -2.62 Million USD | -35.156% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1383.169% |
| CytoDyn Inc. | -18.02 Million USD | 80.326% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -4388.223% |
| Mobile Lads Corp. | -2.24 Million USD | -58.266% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -28904.808% |
| Qrons Inc. | -40.08 Thousand USD | -8749.575% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -630.319% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 772.502% |
| Rebus Holdings, Inc. | -951 Thousand USD | -272.976% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -233.989% |
| International Stem Cell Corporation | 202 Thousand USD | 1855.94% |
| Bioxytran, Inc. | -3.82 Million USD | 7.15% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -6638.218% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -44.074% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 90.111% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -7782.218% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -29.547% |
| Neutra Corp. | -181.24 Thousand USD | -1856.997% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 82.405% |
| PureTech Health plc | -11.62 Million USD | 69.493% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 82.404% |
| IXICO plc | -707 Thousand USD | -401.697% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 53.845% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 92.663% |
| CSL Limited | 4.73 Billion USD | 100.075% |
| Cellectis S.A. | -92.63 Million USD | 96.171% |